Incretin research is one of the most active areas in metabolic science, and the compounds involved are frequently discussed without much precision about what they actually target. This overview compares the receptor profiles of the peptides most often referenced in this literature and separates what is established from what remains investigational.
Key Takeaways
- Incretins are gut-derived hormones that potentiate insulin secretion in response to nutrients; GLP-1 and GIP are the principal examples.
- Research compounds in this space differ by which receptors they engage — one, two, or three — and by structural modifications affecting half-life.
- Some compounds in this family are approved medicines in defined clinical indications; others remain investigational with no approval anywhere.
- Preclinical and early-phase findings for one member of the class do not transfer to another.
- Amino Fuel Labs supplies these compounds strictly as laboratory research materials.
What "Incretin" Means
After a meal, enteroendocrine cells release peptide hormones that amplify pancreatic insulin release beyond what the same glucose load produces intravenously. That amplification is the incretin effect. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are the two hormones responsible in humans.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4. Most research analogs address this by substituting the vulnerable residue, adding a fatty-acid chain that promotes albumin binding, or both — structural strategies that extend circulating half-life substantially.
Glucagon is not an incretin. It is a counter-regulatory pancreatic hormone that raises hepatic glucose output, and it also increases energy expenditure. Some newer research compounds deliberately include glucagon receptor activity alongside incretin activity, which is why it appears in this comparison.
Receptor Profile Comparison
| Compound | GLP-1R | GIPR | Glucagon receptor | Regulatory status |
|---|---|---|---|---|
| Semaglutide | Yes | No | No | Approved medicine in defined indications |
| Tirzepatide | Yes | Yes | No | Approved medicine in defined indications |
| Retatrutide | Yes | Yes | Yes | Investigational; Phase 3 program reporting in 2026 |
| Cagrilintide | No (amylin/calcitonin receptor family) | No | No | Investigational |
| Liraglutide | Yes | No | No | Approved medicine in defined indications |
Retatrutide is a triple agonist under active Phase 3 evaluation; the TRIUMPH program reported topline obesity results during 2026 3 1. Reporting positive trial results is not the same as approval, and as of this article's publication retatrutide is not an approved product.
Cagrilintide is frequently discussed alongside incretins but belongs to a different pharmacology — it is a long-acting amylin analog acting on amylin and calcitonin receptors, studied for satiety signaling rather than incretin potentiation. It remains investigational.
Why Receptor Coverage Matters in Study Design
Adding receptor targets changes what a compound does mechanistically, not simply how strongly it does the same thing.
- GLP-1 receptor activity drives glucose-dependent insulin secretion, slowed gastric emptying, and central satiety signaling.
- GIP receptor activity contributes additional insulinotropic effect and has been studied for its role in adipose tissue biology, where the literature is genuinely unsettled — both agonism and antagonism have been investigated.
- Glucagon receptor activity increases hepatic glucose output and energy expenditure, which is why compounds including it are studied for effects on energy balance rather than glycemia alone.
A study comparing a dual agonist to a single agonist is therefore comparing different mechanisms, and attributing any difference solely to "more potency" is a common misreading.
Reading the Literature Carefully
Three cautions apply to almost every discussion of this class:
- Approval status is compound-specific. Two molecules with overlapping mechanisms can have completely different regulatory positions.
- Trial populations differ. Weight-change percentages from a trial in adults with type 2 diabetes and from a trial in adults without diabetes are not directly comparable — glycemic status materially affects the outcome 4.
- Topline press releases precede peer review. Headline numbers circulate months before full publication, and detail on adverse events, discontinuation, and subgroup results usually arrives later.
For guidance on evaluating source quality, see how to read peptide research studies.
What the Evidence Can—and Cannot—Tell Us
For the approved members of this class, large randomized trials support their use within the specific indications regulators have authorized — and only within those indications, under medical supervision. Nothing on this site is a recommendation for such use.
For investigational members, including retatrutide and cagrilintide, the evidence base consists of clinical trial data that has not resulted in approval. Long-term safety, durability of effect, and outcomes in populations not represented in trials remain open questions. Compounds supplied for laboratory research are not manufactured, labeled, or intended for human use, and no research-grade material should be treated as equivalent to an approved medicine.
Frequently Asked Questions
Is retatrutide approved? No. It is an investigational triple agonist. Phase 3 obesity trials reported topline results during 2026 1, but reporting results is not approval.
Is cagrilintide an incretin? No. It is an amylin analog acting through the amylin and calcitonin receptor family, studied for satiety signaling.
Does triple-receptor activity mean a compound is better? It means the mechanism differs. Whether that translates to a better outcome in any given endpoint is an empirical question answered per trial, not by counting receptors.
Can research-grade material be compared to an approved medicine? No. Research materials are supplied for laboratory study, are not manufactured as medicines, and are not intended for human use.
References
- Eli Lilly investor release — TRIUMPH-1 topline
- BioSpace — TRIUMPH-2 and TRIUMPH-3 topline coverage
- ClinicalTrials.gov
- FDA — Drug approvals and databases
Continue Reading
Continue with how to read peptide research studies, or view lab reports and current research materials.
Amino Fuel Labs products are sold strictly for laboratory research use only. They are not intended for human or veterinary use, consumption, diagnosis, treatment, cure, or prevention of disease. This article is educational and is not medical advice.
